Results 221 to 230 of about 134,446 (292)

Lower proportion of CD19 + IL-10 + and CD19 + CD24 + CD27 + but not CD1d + CD5 + CD19 + CD24 + CD27 + IL-10

Autoimmunity, 2020
openaire   +1 more source

Minimal residual disease–guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype

British Journal of Haematology, EarlyView.
Minimal residual disease (MRD)–guided ibrutinib and venetoclax (IVen) achieved durable remissions and high undetectable MRD (uMRD) rates in patients with high‐risk chronic lymphocytic leukaemia (CLL). Compared with historical ibrutinib monotherapy, IVen was associated with improved progression‐free and overall survival despite presence of complex ...
Maria Kislova, Elena Dmitrieva, Elena Naumova, Margarita Pochtar, Svetlana Lugovskaya, Yury Kobzev, Alla Loban, Maria Gladysheva, Tatiana Obukhova, Bella Biderman, Andrey Sudarikov, Egor Volchkov, Maria Ivanova, Vadim Ptushkin, Andrea Visentin, Eugene Nikitin   +15 more
wiley   +1 more source

Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series. [PDF]

Cell Rep Med
Hegelmaier T, Motte J, Walther D, Feist E, Duscha A, Desel C, Pappa V, Böttcher M, Voigt M, Sgodzai M, Al-Dubai M, Schroers R, Borie D, Schett G, Mougiakakos D, Gold R, Haghikia A.   +16 more
europepmc   +1 more source

Increased anergic B cells and decreased antibody‐secreting cells during romiplostim treatment in patients with immune thrombocytopenia

British Journal of Haematology, EarlyView.
Summary Patients with immune thrombocytopenia (ITP) exhibit substantial heterogeneity in treatment responses. Approximately 30%–50% of patients maintain remission after discontinuation of thrombopoietin receptor agonists (TPO‐RA), suggesting immunomodulatory effects beyond enhanced thrombopoiesis.
Vivianne S. Nelson, Rebeca Gutiérrez‐Cózar, Rebecca Cornelis, S. Marieke van Ham, Anja ten Brinke, Rick Kapur   +5 more
wiley   +1 more source

Predicted microbiome‐associated metabolic pathways are linked to immune checkpoint modulation in chronic lymphocytic leukaemia

British Journal of Haematology, EarlyView.
Summary Microbial metabolites are key regulators of host immunity, yet their functional impact in chronic lymphocytic leukaemia (CLL) remains unclear. Following up on our earlier observations of microbiome dysbiosis in CLL, we performed predictive metabolic profiling based on 16S ribosomal RNA (rRNA) sequencing of oral and stool samples collected from ...
Monika Szelest, Joanna Zaleska, Michał Kiełbus, Magdalena Paziewska, Marta Masternak, Ewa Wawrzyniak, Aleksandra Kotkowska, Monika Siemieniuk‐Ryś, Marta Morawska, Elżbieta Kalicińska, Paula Jabłonowska‐Babij, Tomasz Wróbel, Anna Wolska‐Washer, Jerzy Zdzisław Błoński, Tadeusz Robak, Krzysztof Giannopoulos   +15 more
wiley   +1 more source

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma. [PDF]

Blood Cancer Discov
Yang H, Arita K, Bowman K, Chihara D, Henderson J, Rost G, Rojas E, Parsons S, Lakra P, Abedin AS, Neelapu SS, Strati P, Nastoupil LJ, Fayad LE, Iyer SP, Rodriguez MA, Hagemeister FB, Malpica L, Lee H, Hilton LK, Scott DW, Davis RE, Flowers CR, Westin JR, Inghirami G, Vega F, Green MR.   +26 more
europepmc   +1 more source

Blinatumomab as the first-line induction for ANCA-associated rapidly progressive glomerulonephritis. [PDF]

RMD Open
Wang J, Yu Y, Li R, Shi B, Wu W, Ding H, Du F, Ye S, Chen S.   +8 more
europepmc   +1 more source

Diagnostic Ambiguity in BCR-ABL1-Positive MPAL in a Resource-Limited Setting: A Case Report. [PDF]

Case Rep Hematol
Poudel S, Sharma S, Kafle S, Karki S, Shrestha A.   +4 more
europepmc   +1 more source